Ionis Pharmaceuticals (IONS) EVP Swayze logs preset stock sales

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP Research Eric Swayze reported preset stock sales. On February 13, 2026, he executed two open-market sales of Ionis common stock under a Rule 10b5-1 trading plan adopted on August 14, 2024.

The transactions totaled 9,435 shares at $81.5592 and 6,207 shares at $82.0691 weighted-average prices. After these sales, Swayze held 32,105 shares directly and 318 shares indirectly through his son.

Insider Trade Summary

Net Seller: 15,642 shares ($1,278,914)

Net Sell 3 txns

Insider Swayze Eric

Role EVP Research

Sold 15,642 shs ($1.28M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,435	$81.5592	$770K
Sale	Common Stock	6,207	$82.0691	$509K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 38,312 shares (Direct); Common Stock — 318 shares (Indirect, by Son)

Footnotes (1)

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.76 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.315 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Form 4 Insider Transactions: What Each Field Means →

02/13/2026 - 07:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swayze Eric

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Research

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/13/2026		S		9,435⁽¹⁾	D	$81.5592⁽²⁾	38,312	D
Common Stock	02/13/2026		S		6,207⁽¹⁾	D	$82.0691⁽³⁾	32,105	D
Common Stock								318	I	by Son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.76 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.315 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did IONIS PHARMACEUTICALS INC (IONS) report for Eric Swayze?

Eric Swayze reported two open-market sales of Ionis common stock. On February 13, 2026, he sold 9,435 shares and 6,207 shares in separate transactions, both disclosed on a Form 4 insider trading report.

How many IONS shares did Eric Swayze sell on February 13, 2026?

Eric Swayze sold 15,642 Ionis shares in total on February 13, 2026. The sales were split into 9,435 shares in one trade and 6,207 shares in another, both reported as open-market transactions.

At what prices did Eric Swayze sell his IONIS PHARMACEUTICALS INC shares?

Eric Swayze’s Ionis share sales used weighted-average prices. One block of 9,435 shares priced at $81.5592 and another 6,207 shares at $82.0691, each representing multiple trades within the stated price ranges.

Was the IONS insider sale by Eric Swayze under a 10b5-1 trading plan?

Yes, the reported Ionis stock sales were made under a Rule 10b5-1 trading plan. The filing states the plan was adopted by Eric Swayze on August 14, 2024, indicating the transactions were pre-arranged rather than discretionary.

How many IONIS shares does Eric Swayze own after the reported sales?

After the February 13, 2026 sales, Eric Swayze beneficially owned 32,105 Ionis shares directly. The filing also reports indirect beneficial ownership of 318 additional shares held by his son, as disclosed in the ownership table.

What is Eric Swayze’s role at IONIS PHARMACEUTICALS INC in this Form 4?

In this Form 4, Eric Swayze is identified as an officer of Ionis Pharmaceuticals. His specific title is Executive Vice President, Research, and he is not reported as a director or 10% beneficial owner in the checked boxes.